Here's How Intrexon Might Prove Me Wrong
I've been quick to point out when marketing hype doesn't match up with what's realistically possible from a technical standpoint. Unfortunately, in my opinion, there have been many such instances in the early stages of the industrial biotech industry.
That's why I've strongly argued that investors should temper expectations regarding the natural-gas-to-chemicals technology platform being developed by engineered biology conglomerate Intrexon (NYSE: XON).
But science is often about having an open mind. At the end of July, I traveled to the BIO World Congress on Industrial Biotechnology in Montreal, where I caught up with Intrexon Energy Senior Vice President Bob Walsh. We discussed the novel technology platform under development and why Intrexon thinks it's going to prove me wrong.
Source: Fool.com
Equinor ASA ADR Stock
The community is currently still undecided about Equinor ASA ADR with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 38 € shows a positive potential of 47.29% compared to the current price of 25.8 € for Equinor ASA ADR.
